Regulation of expression and function of IDO in human dendritic cells

Current Medicinal Chemistry

Volumn 18, Issue 15, 2011, Pages 2222-2233

  Heitger, A ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Dendritic cells; Human; Immune response; Indoleamine 2,3 dioxygenase; Kynurenines; Tryptophan metabolism

Indexed keywords

1 METHYLTRYPTOPHAN; 3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 12; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE; KYNURENINE; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; QUINOLINIC ACID; SMALL INTERFERING RNA; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; THYMOSIN ALPHA1; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CHLAMYDIA; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG RECEPTOR BINDING; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; MOLECULE; NEGATIVE FEEDBACK; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TH3 CELL; TOXOPLASMA GONDII; TRANSCRIPTION REGULATION; TRYPTOPHAN METABOLISM;

EID: 79957941172     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795656018     Document Type: Article

References (149)

1. Steinman, R.M.; Cohn, Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med., 1973, 137(5), 1142-1162.
2. Shortman, K.; Naik, S.H. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol., 2007, 7(1), 19-30. (Pubitemid 46020824)
3. Shortman, K.; Liu, Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol., 2002, 2(3), 151-161. (Pubitemid 37336516)
4. Merad, M.; Manz, M.G. Dendritic cell homeostasis. Blood, 2009, 113(15), 3418-3427.
5. Heath, W.R.; Carbone, F.R. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat. Immunol., 2009, 10(12), 1237-1244.
6. Villadangos, J.A.; Schnorrer, P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol., 2007, 7(7), 543-555. (Pubitemid 46987783)
7. Reis e Sousa, C. Dendritic cells in a mature age. Nat. Rev. Immunol., 2006, 6(6), 476-483.
8. Liu, Y.J.; Kanzler, H.; Soumelis, V.; Gilliet, M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol., 2001, 2(7), 585-589. (Pubitemid 32677624)
9. Hume, D.A. Macrophages as APC and the dendritic cell myth. J. Immunol., 2008, 181(9), 5829-5835.
10. Schultze, J.; Nadler, L.M.; Gribben, J.G. B7-mediated costimulation and the immune response. Blood Rev., 1996, 10(2), 111-127. (Pubitemid 26234220)
11. Wilson, N.S.; Villadangos, J.A. Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm. Immunol. Cell Biol., 2004, 82(1), 91-98. (Pubitemid 38388725)
12. Gallucci, S.; Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol., 2001, 13(1), 114-119. (Pubitemid 32096970)
13. Kalinski, P.; Hilkens, C.M.; Wierenga, E.A.; Kapsenberg, M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today, 1999, 20(12), 561-567.
14. Rutella, S.; Danese, S.; Leone, G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood, 2006, 108(5), 1435-1440. (Pubitemid 44316106)
15. Morelli, A.E.; Thomson, A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol., 2007, 7(8), 610-621. (Pubitemid 47123548)
16. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 2005, 5(4), 263-274. (Pubitemid 40488632)
17. Chui, C.S.; Li, D. Role of immunolglobulin-like transcript family receptors and their ligands in suppressor T-cell-induced dendritic cell tolerization. Hum. Immunol., 2009, 70(9), 686-691.
18. Chang, C.C.; Ciubotariu, R.; Manavalan, J.S.; Yuan, J.; Colovai, A.I.; Piazza, F.; Lederman, S.; Colonna, M.; Cortesini, R.; Dalla-Favera, R.; Suciu-Foca, N. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol., 2002, 3(3), 237-243. (Pubitemid 34218114)
19. Sato, K.; Yamashita, N.; Baba, M.; Matsuyama, T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood, 2003, 101(9), 3581-3589. (Pubitemid 36857945)
20. Dumitriu, I.E.; Dunbar, D.R.; Howie, S.E.; Sethi, T.; Gregory, C.D. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol., 2009, 182(5), 2795-2807.
21. Ilarregui, J.M.; Croci, D.O.; Bianco, G.A.; Toscano, M.A.; Salatino, M.; Vermeulen, M.E.; Geffner, J.R.; Rabinovich, G.A. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol., 2009, 10(9), 981-991.
22. Ehser, S.; Chuang, J.J.; Kleist, C.; Sandra-Petrescu, F.; Iancu, M.; Wang, D.; Opelz, G.; Terness, P. Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum. Immunol., 2008, 69(3), 165-173.
23. Adorini, L.; Penna, G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol., 2009, 70(5), 345-352.
24. Piemonti, L.; Monti, P.; Sironi, M.; Fraticelli, P.; Leone, B.E.; Dal Cin, E.; Allavena, P.; Di Carlo, V. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol., 2000, 164(9), 4443-4451. (Pubitemid 30238038)
25. Rosenblatt, J.; Bissonnette, A.; Ahmad, R.; Wu, Z.; Vasir, B.; Stevenson, K.; Zarwan, C.; Keefe, W.; Glotzbecker, B.; Mills, H.; Joyce, R.; Levine, J.D.; Tzachanis, D.; Boussiotis, V.; Kufe, D.; Avigan, D. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant., 2010, 45(9), 1463-1468.
26. Bronte, V.; Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol., 2005, 5(8), 641-654. (Pubitemid 41113195)
27. Moffett, J.R.; Namboodiri, M.A. Tryptophan and the immune response. Immunol. Cell Biol., 2003, 81(4), 247-265. (Pubitemid 36904332)
28. Guillemin, G.J.; Cullen, K.M.; Lim, C.K.; Smythe, G.A.; Garner, B.; Kapoor, V.; Takikawa, O.; Brew, B.J. Characterization of the kynurenine pathway in human neurons. J. Neurosci., 2007, 27(47), 12884-12892. (Pubitemid 350161746)
29. Grohmann, U.; Fallarino, F.; Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol., 2003, 24(5), 242-248. (Pubitemid 36555962)
30. Thackray, S.J.; Mowat, C.G.; Chapman, S.K. Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem. Soc. Trans., 2008, 36(Pt 6), 1120-1123.
31. Shimizu, T.; Nomiyama, S.; Hirata, F.; Hayaishi, O. Indoleamine 2,3- dioxygenase. Purification and some properties. J. Biol. Chem., 1978, 253(13), 4700-4706. (Pubitemid 8372084)
32. Pfefferkorn, E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. U. S. A., 1984, 81(3), 908-912. (Pubitemid 14197611)
33. Byrne, G.I.; Lehmann, L.K.; Landry, G.J. Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect. Immun., 1986, 53(2), 347-351. (Pubitemid 16073864)
34. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 1998, 281(5380), 1191-1193. (Pubitemid 28406294)
35. Hainz, U.; Jurgens, B.; Heitger, A. The role of indoleamine 2,3-dioxygenase in transplantation. Transpl. Int., 2007, 20(2), 118-127. (Pubitemid 46121989)
36. Muller, A.J.; Prendergast, G.C. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res., 2005, 65(18), 8065-8068. (Pubitemid 41330565)
37. Correale, J.; Ysrraelit, M.C.; Gaitan, M.I. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain, 2009, 132(Pt 5), 1146-1160.
38. Boasso, A.; Hardy, A.W.; Anderson, S.A.; Dolan, M.J.; Shearer, G.M. HIVinduced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One, 2008, 3(8), e2961.
39. Murray, M.F. Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect. Dis., 2003, 3(10), 644-652. (Pubitemid 37210228)
40. Boasso, A.; Herbeuval, J.P.; Hardy, A.W.; Winkler, C.; Shearer, G.M. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNAsynthetase by CTLA-4-Fc in human CD4+ T cells. Blood, 2005, 105(4), 1574-1581. (Pubitemid 40223677)
41. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity, 2005, 22(5), 633-642. (Pubitemid 40719198)
42. Metz, R.; Duhadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res., 2007, 67(15), 7082-7087. (Pubitemid 47206533)
43. Descombes, P.; Schibler, U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell, 1991, 67(3), 569-579. (Pubitemid 121001471)
44. Rohde, J.; Heitman, J.; Cardenas, M.E. The TOR kinases link nutrient sensing to cell growth. J. Biol. Chem., 2001, 276(13), 9583-9586.
45. Mellor, A.L.; Chandler, P.; Baban, B.; Hansen, A.M.; Marshall, B.; Pihkala, J.; Waldmann, H.; Cobbold, S.; Adams, E.; Munn, D.H. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol., 2004, 16(10), 1391-1401. (Pubitemid 39341552)
46. Hill, M.; Tanguy-Royer, S.; Royer, P.; Chauveau, C.; Asghar, K.; Tesson, L.; Lavainne, F.; Remy, S.; Brion, R.; Hubert, F.X.; Heslan, M.; Rimbert, M.; Berthelot, L.; Moffett, J.R.; Josien, R.; Gregoire, M.; Anegon, I. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol., 2007, 37(11), 3054-3062. (Pubitemid 350131285)
47. Chen, W.; Liang, X.; Peterson, A.J.; Munn, D.H.; Blazar, B.R. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol., 2008, 181(8), 5396-5404.
48. Chung, D.J.; Rossi, M.; Romano, E.; Ghith, J.; Yuan, J.; Munn, D.H.; Young, J.W. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 2009, 114(3), 555-563.
49. Jurgens, B.; Hainz, U.; Fuchs, D.; Felzmann, T.; Heitger, A. Interferongamma- triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood, 2009, 114(15), 3235-3243.
50. Colonna, M.; Krug, A.; Cella, M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol., 2002, 14(3), 373-379. (Pubitemid 34327981)
51. Fallarino, F.; Asselin-Paturel, C.; Vacca, C.; Bianchi, R.; Gizzi, S.; Fioretti, M.C.; Trinchieri, G.; Grohmann, U.; Puccetti, P. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J. Immunol., 2004, 173(6), 3748-3754. (Pubitemid 39280736)
52. Munn, D.H.; Sharma, M.D.; Hou, D.; Baban, B.; Lee, J.R.; Antonia, S.J.; Messina, J.L.; Chandler, P.; Koni, P.A.; Mellor, A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumordraining lymph nodes. J. Clin. Invest., 2004, 114(2), 280-290. (Pubitemid 39071633)
53. Mellor, A.L.; Baban, B.; Chandler, P.; Marshall, B.; Jhaver, K.; Hansen, A.; Koni, P.A.; Iwashima, M.; Munn, D.H. Cutting edge: induced indoleamine2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol., 2003, 171(4), 1652-1655. (Pubitemid 36966447)
54. Fallarino, F.; Gizzi, S.; Mosci, P.; Grohmann, U.; Puccetti, P. Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr. Drug Metab., 2007, 8(3), 209-216. (Pubitemid 46628286)
55. Najfeld, V.; Menninger, J.; Muhleman, D.; Comings, D.E.; Gupta, S.L. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12->p11 by fluorescent in situ hybridization. Cytogenet. Cell Genet., 1993, 64(3-4), 231-232. (Pubitemid 23309628)
56. Konan, K.V.; Taylor, M.W. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J. Biol. Chem., 1996, 271(32), 19140-19145. (Pubitemid 26271576)
57. Hassanain, H.H.; Chon, S.Y.; Gupta, S.L. Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-gamma and - alpha. Analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor. J. Biol. Chem., 1993, 268(7), 5077-5084. (Pubitemid 23081633)
58. Puccetti, P. On watching the watchers: IDO and type I/II IFN. Eur. J. Immunol., 2007, 37(4), 876-879. (Pubitemid 46925324)
59. Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene, 2007, 396(1), 203-213. (Pubitemid 46818792)
60. Chon, S.Y.; Hassanain, H.H.; Gupta, S.L. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferongamma- inducible expression of human indoleamine 2,3-dioxygenase gene. J. Biol. Chem., 1996, 271(29), 17247-17252. (Pubitemid 26244281)
61. Silva, N.M.; Rodrigues, C.V.; Santoro, M.M.; Reis, L.F.; Alvarez-Leite, J.I.; Gazzinelli, R.T. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. Infect. Immun., 2002, 70(2), 859-868. (Pubitemid 34083850)
62. Jung, I.D.; Lee, C.M.; Jeong, Y.I.; Lee, J.S.; Park, W.S.; Han, J.; Park, Y.M. Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells. FEBS Lett., 2007, 581(7), 1449-1456. (Pubitemid 46463960)
63. Fujigaki, S.; Saito, K.; Sekikawa, K.; Tone, S.; Takikawa, O.; Fujii, H.; Wada, H.; Noma, A.; Seishima, M. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gammaindependent mechanism. Eur. J. Immunol., 2001, 31(8), 2313-2318. (Pubitemid 32785349)
64. Fujigaki, H.; Saito, K.; Fujigaki, S.; Takemura, M.; Sudo, K.; Ishiguro, H.; Seishima, M. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J. Biochem., 2006, 139(4), 655-662. (Pubitemid 43973911)
65. Braun, D.; Longman, R.S.; Albert, M.L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood, 2005, 106(7), 2375-2381. (Pubitemid 41510810)
66. Orabona, C.; Tomasello, E.; Fallarino, F.; Bianchi, R.; Volpi, C.; Bellocchio, S.; Romani, L.; Fioretti, M.C.; Vivier, E.; Puccetti, P.; Grohmann, U. Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur. J. Immunol., 2005, 35(11), 3111-3118. (Pubitemid 41672516)
67. Orabona, C.; Puccetti, P.; Vacca, C.; Bicciato, S.; Luchini, A.; Fallarino, F.; Bianchi, R.; Velardi, E.; Perruccio, K.; Velardi, A.; Bronte, V.; Fioretti, M.C.; Grohmann, U. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood, 2006, 107(7), 2846-2854.
68. Puccetti, P.; Grohmann, U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol., 2007, 7(10), 817-823. (Pubitemid 47480306)
69. Tas, S.W.; Vervoordeldonk, M.J.; Hajji, N.; Schuitemaker, J.H.; van der Sluijs, K.F.; May, M.J.; Ghosh, S.; Kapsenberg, M.L.; Tak, P.P.; de Jong, E.C. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood, 2007, 110(5), 1540-1549. (Pubitemid 47443970)
70. Goodwin, J.S.; Bankhurst, A.D.; Messner, R.P. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J. Exp. Med., 1977, 146(6), 1719-1734. (Pubitemid 8245453)
71. Kalinski, P.; Vieira, P.L.; Schuitemaker, J.H.; de Jong, E.C.; Kapsenberg, M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL- 12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood, 2001, 97(11), 3466-3469.
72. Hwu, P.; Du, M.X.; Lapointe, R.; Do, M.; Taylor, M.W.; Young, H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol., 2000, 164(7), 3596-3599. (Pubitemid 30169812)
73. Colonna, M.; Trinchieri, G.; Liu, Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol., 2004, 5(12), 1219-1226. (Pubitemid 41057736)
74. Boasso, A.; Herbeuval, J.P.; Hardy, A.W.; Anderson, S.A.; Dolan, M.J.; Fuchs, D.; Shearer, G.M. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood, 2007, 109(8), 3351-3359. (Pubitemid 46572523)
75. Manches, O.; Munn, D.; Fallahi, A.; Lifson, J.; Chaperot, L.; Plumas, J.; Bhardwaj, N. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest., 2008, 118(10), 3431-3439.
76. Hirata, F.; Ohnishi, T.; Hayaishi, O. Indoleamine 2,3-dioxygenase. Characterization and properties of enzyme. O2- complex. J. Biol. Chem., 1977, 252(13), 4637-4642. (Pubitemid 8155985)
77. Werner, E.R.; Werner-Felmayer, G. Substrate and cofactor requirements of indoleamine 2,3-dioxygenase in interferon-gamma-treated cells: utilization of oxygen rather than superoxide. Curr. Drug Metab., 2007, 8(3), 201-203. (Pubitemid 46621670)
78. Maghzal, G.J.; Thomas, S.R.; Hunt, N.H.; Stocker, R. Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3- dioxygenase in human cells. J. Biol. Chem., 2008, 283(18), 12014-12025.
79. Sono, M.; Taniguchi, T.; Watanabe, Y.; Hayaishi, O. Indoleamine 2,3- dioxygenase. Equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes. J. Biol. Chem., 1980, 255(4), 1339-1345.
80. Hill, M.; Pereira, V.; Chauveau, C.; Zagani, R.; Remy, S.; Tesson, L.; Mazal, D.; Ubillos, L.; Brion, R.; Asghar, K.; Mashreghi, M.F.; Kotsch, K.; Moffett, J.; Doebis, C.; Seifert, M.; Boczkowski, J.; Osinaga, E.; Anegon, I. Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J., 2005, 19(14), 1957-1968. (Pubitemid 41759741)
81. Thomas, S.R.; Terentis, A.C.; Cai, H.; Takikawa, O.; Levina, A.; Lay, P.A.; Freewan, M.; Stocker, R. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J. Biol. Chem., 2007, 282(33), 23778-23787. (Pubitemid 47328013)
82. Hainz, U.; Jurgens, B.; Wekerle, T.; Seidel, M.G.; Heitger, A. Indoleamine 2,3-dioxygenase in hematopoietic stem cell transplantation. Curr. Drug Metab., 2007, 8(3), 267-272. (Pubitemid 46621675)
83. Prendergast, G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene, 2008, 27(28), 3889-3900. (Pubitemid 351913639)
84. Kelchtermans, H.; Billiau, A.; Matthys, P. How interferon-gamma keeps autoimmune diseases in check. Trends. Immunol., 2008, 29(10), 479-486.
85. Konieczny, B.T.; Dai, Z.; Elwood, E.T.; Saleem, S.; Linsley, P.S.; Baddoura, F.K.; Larsen, C.P.; Pearson, T.C.; Lakkis, F.G. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J. Immunol., 1998, 160(5), 2059-2064. (Pubitemid 28119882)
86. Langenkamp, A.; Messi, M.; Lanzavecchia, A.; Sallusto, F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol., 2000, 1(4), 311-316.
87. Felzmann, T.; Huttner, K.G.; Breuer, S.K.; Wimmer, D.; Ressmann, G.; Wagner, D.; Paul, P.; Lehner, M.; Heitger, A.; Holter, W. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol. Immunother., 2005, 54(8), 769-780. (Pubitemid 40977145)
88. Grohmann, U.; Orabona, C.; Fallarino, F.; Vacca, C.; Calcinaro, F.; Falorni, A.; Candeloro, P.; Belladonna, M.L.; Bianchi, R.; Fioretti, M.C.; Puccetti, P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol., 2002, 3(11), 1097-1101. (Pubitemid 35363664)
89. Fallarino, F.; Grohmann, U.; Hwang, K.W.; Orabona, C.; Vacca, C.; Bianchi, R.; Belladonna, M.L.; Fioretti, M.C.; Alegre, M.L.; Puccetti, P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol., 2003, 4(12), 1206-1212. (Pubitemid 37547898)
90. Grohmann, U.; Volpi, C.; Fallarino, F.; Bozza, S.; Bianchi, R.; Vacca, C.; Orabona, C.; Belladonna, M.L.; Ayroldi, E.; Nocentini, G.; Boon, L.; Bistoni, F.; Fioretti, M.C.; Romani, L.; Riccardi, C.; Puccetti, P. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat. Med., 2007, 13(5), 579-586. (Pubitemid 46828479)
91. Munn, D.H.; Sharma, M.D.; Mellor, A.L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol., 2004, 172(7), 4100-4110. (Pubitemid 38375222)
92. Pree, I.; Bigenzahn, S.; Fuchs, D.; Koporc, Z.; Nierlich, P.; Winkler, C.; Brandacher, G.; Sykes, M.; Muehlbacher, F.; Langer, F.; Wekerle, T. CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of Indoleamine-2,3-dioxygenase. Transplantation, 2007, 83(5), 663-667. (Pubitemid 46440260)
93. Davis, P.M.; Nadler, S.G.; Stetsko, D.K.; Suchard, S.J. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin. Immunol., 2008, 126(1), 38-47. (Pubitemid 350266453)
94. Munn, D.H.; Shafizadeh, E.; Attwood, J.T.; Bondarev, I.; Pashine, A.; Mellor, A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med., 1999, 189(9), 1363-1372. (Pubitemid 29227522)
95. Terness, P.; Chuang, J.J.; Bauer, T.; Jiga, L.; Opelz, G. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)- producing dendritic cells: too much ado about IDO? Blood, 2005, 105(6), 2480-2486. (Pubitemid 40387049)
96. Munn, D.H.; Mellor, A.L.; Rossi, M.; Young, J.W. Dendritic cells have the option to express IDO-mediated suppression or not. Blood, 2005, 105(6), 2618. (Pubitemid 40387070)
97. Krause, P.; Singer, E.; Darley, P.I.; Klebensberger, J.; Groettrup, M.; Legler, D.F. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J. Leukoc. Biol., 2007, 82(5), 1106-1114. (Pubitemid 350133506)
98. Terness, P.; Chuang, J.J.; Opelz, G. The immunoregulatory role of IDOproducing human dendritic cells revisited. Trends. Immunol., 2006, 27(2), 68-73. (Pubitemid 43221972)
99. Fallarino, F.; Grohmann, U.; You, S.; McGrath, B.C.; Cavener, D.R.; Vacca, C.; Orabona, C.; Bianchi, R.; Belladonna, M.L.; Volpi, C.; Fioretti, M.C.; Puccetti, P. Tryptophan catabolism generates autoimmune-preventive regulatory T cells. Transpl. Immunol., 2006, 17(1), 58-60. (Pubitemid 44828801)
100. Curti, A.; Pandolfi, S.; Valzasina, B.; Aluigi, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; Rutella, S.; Durelli, I.; Horenstein, A.L.; Fiore, F.; Massaia, M.; Colombo, M.P.; Baccarani, M.; Lemoli, R.M. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood, 2007, 109(7), 2871-2877. (Pubitemid 46482083)
101. Fallarino, F.; Grohmann, U.; Vacca, C.; Bianchi, R.; Orabona, C.; Spreca, A.; Fioretti, M.C.; Puccetti, P. T cell apoptosis by tryptophan catabolism. Cell Death Differ., 2002, 9(10), 1069-1077.
102. Lee, G.K.; Park, H.J.; Macleod, M.; Chandler, P.; Munn, D.H.; Mellor, A.L. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology, 2002, 107(4), 452-460. (Pubitemid 36693650)
103. Terness, P.; Bauer, T.M.; Rose, L.; Dufter, C.; Watzlik, A.; Simon, H.; Opelz, G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3- dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med., 2002, 196(4), 447-457.
104. Della Chiesa, M.; Carlomagno, S.; Frumento, G.; Balsamo, M.; Cantoni, C.; Conte, R.; Moretta, L.; Moretta, A.; Vitale, M. The tryptophan catabolite Lkynurenine inhibits the surface expression of NKp46- and NKG2Dactivating receptors and regulates NK-cell function. Blood, 2006, 108(13), 4118-4125. (Pubitemid 44913283)
105. Mellor, A.L.; Munn, D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol., 2004, 4(10), 762-774. (Pubitemid 39336293)
106. Lob, S.; Konigsrainer, A.; Rammensee, H.G.; Opelz, G.; Terness, P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer, 2009, 9(6), 445-452.
107. Munn, D.H.; Sharma, M.D.; Lee, J.R.; Jhaver, K.G.; Johnson, T.S.; Keskin, D.B.; Marshall, B.; Chandler, P.; Antonia, S.J.; Burgess, R.; Slingluff, C.L. Jr.; Mellor, A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 2002, 297(5588), 1867-1870. (Pubitemid 35024345)
108. Hainz, U.; Obexer, P.; Winkler, C.; Sedlmayr, P.; Takikawa, O.; Greinix, H.; Lawitschka, A.; Potschger, U.; Fuchs, D.; Ladisch, S.; Heitger, A. Monocytemediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation. Blood, 2005, 105(10), 4127-4134. (Pubitemid 40656165)
109. Brenk, M.; Scheler, M.; Koch, S.; Neumann, J.; Takikawa, O.; Hacker, G.; Bieber, T.; von Bubnoff, D. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. J. Immunol., 2009, 183(1), 145-154.
110. Lopez, A.S.; Alegre, E.; LeMaoult, J.; Carosella, E.; Gonzalez, A. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol. Immunol., 2006, 43(14), 2151-2160. (Pubitemid 43831200)
111. Driesen, J.; Popov, A.; Schultze, J.L. CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology, 2008, 213(9-10), 849-858.
112. Sharma, M.D.; Baban, B.; Chandler, P.; Hou, D.Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B.R.; Mellor, A.L.; Munn, D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest., 2007, 117(9), 2570-2582. (Pubitemid 47494358)
113. Agaugue, S.; Perrin-Cocon, L.; Coutant, F.; Andre, P.; Lotteau, V. 1-Methyltryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol., 2006, 177(4), 2061-2071. (Pubitemid 44200963)
114. Lob, S.; Konigsrainer, A.; Schafer, R.; Rammensee, H.G.; Opelz, G.; Terness, P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood, 2008, 111(4), 2152-2154. (Pubitemid 351451527)
115. Okamoto, T.; Tone, S.; Kanouchi, H.; Miyawaki, C.; Ono, S.; Minatogawa, Y. Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue : Down-regulation of the indoleamine 2,3- dioxygenase (IDO) transcription by tryptophan and its analogue. Cytotechnology, 2007, 54(2), 107-113. (Pubitemid 47174823)
116. Popov, A.; Abdullah, Z.; Wickenhauser, C.; Saric, T.; Driesen, J.; Hanisch, F.G.; Domann, E.; Raven, E.L.; Dehus, O.; Hermann, C.; Eggle, D.; Debey, S.; Chakraborty, T.; Kronke, M.; Utermohlen, O.; Schultze, J.L. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J. Clin. Invest., 2006, 116(12), 3160-3170. (Pubitemid 44878630)
117. Romani, L.; Fallarino, F.; De Luca, A.; Montagnoli, C.; D'Angelo, C.; Zelante, T.; Vacca, C.; Bistoni, F.; Fioretti, M.C.; Grohmann, U.; Segal, B.H.; Puccetti, P. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature, 2008, 451(7175), 211-215.
118. Zelante, T.; Fallarino, F.; Bistoni, F.; Puccetti, P.; Romani, L. Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes. Infect., 2009, 11(1), 133-141.
119. Desvignes, L.; Ernst, J.D. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium tuberculosis. Immunity, 2009, 31(6), 974-985.
120. Sharma, M.D.; Hou, D.Y.; Liu, Y.; Koni, P.A.; Metz, R.; Chandler, P.; Mellor, A.L.; He, Y.; Munn, D.H. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood, 2009, 113(24), 6102-6111.
121. Bianchi, M.; Hakkim, A.; Brinkmann, V.; Siler, U.; Seger, R.A.; Zychlinsky, A.; Reichenbach, J. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood, 2009, 114(13), 2619-2622.
122. Poliani, P.L.; Kisand, K.; Marrella, V.; Ravanini, M.; Notarangelo, L.D.; Villa, A.; Peterson, P.; Facchetti, F. Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. Am. J. Pathol., 2010, 176(3), 1104-1112.
123. Tan, P.H.; Bharath, A.K. Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases. Expert Opin. Ther. Targets., 2009, 13(8), 987-1012.
124. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 2004, 21(2), 137-148. (Pubitemid 39094044)
125. Katz, J.B.; Muller, A.J.; Prendergast, G.C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev., 2008, 222, 206-221. (Pubitemid 351430372)
126. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3- dioxygenase. Nat. Med., 2003, 9(10), 1269-1274. (Pubitemid 37279849)
127. Emens, L.A.; Jaffee, E.M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res., 2005, 65(18), 8059-8064. (Pubitemid 41330564)
128. Polak, L.; Turk, J.L. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature, 1974, 249(458), 654-656.
129. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M.C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F.J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J.P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4- dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med., 2007, 13(9), 1050-1059. (Pubitemid 47517504)
130. Muller, A.J.; Malachowski, W.P.; Prendergast, G.C. Indoleamine 2,3- dioxygenase in cancer: targeting pathological immune tolerance with smallmolecule inhibitors. Expert Opin. Ther. Targets., 2005, 9(4), 831-849. (Pubitemid 41131682)
131. Windbichler, G.H.; Hausmaninger, H.; Stummvoll, W.; Graf, A.H.; Kainz, C.; Lahodny, J.; Denison, U.; Muller-Holzner, E.; Marth, C. Interferongamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer, 2000, 82(6), 1138-1144. (Pubitemid 30128869)
132. Giannopoulos, A.; Constantinides, C.; Fokaeas, E.; Stravodimos, C.; Giannopoulou, M.; Kyroudi, A.; Gounaris, A. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin. Cancer Res., 2003, 9(15), 5550-5558. (Pubitemid 37499474)
133. Morse, M.A.; Coleman, R.E.; Akabani, G.; Niehaus, N.; Coleman, D.; Lyerly, H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res., 1999, 59(1), 56-58. (Pubitemid 29062955)
134. Wobser, M.; Voigt, H.; Houben, R.; Eggert, A.O.; Freiwald, M.; Kaemmerer, U.; Kaempgen, E.; Schrama, D.; Becker, J.C. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol. Immunother., 2007, 56(7), 1017-1024. (Pubitemid 46675300)
135. Flatekval, G.F.; Sioud, M. Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology, 2009, 128(1 Suppl), e837-848.
136. Maneechotesuwan, K.; Wamanuttajinda, V.; Kasetsinsombat, K.; Huabprasert, S.; Yaikwawong, M.; Barnes, P.J.; Wongkajornsilp, A. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. J. Allergy Clin. Immunol., 2009, 123(1), 239-248.
137. Platten, M.; Ho, P.P.; Youssef, S.; Fontoura, P.; Garren, H.; Hur, E.M.; Gupta, R.; Lee, L.Y.; Kidd, B.A.; Robinson, W.H.; Sobel, R.A.; Selley, M.L.; Steinman, L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science, 2005, 310(5749), 850-855. (Pubitemid 41567343)
138. Alexander, A.M.; Crawford, M.; Bertera, S.; Rudert, W.A.; Takikawa, O.; Robbins, P.D.; Trucco, M. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes, 2002, 51(2), 356-365. (Pubitemid 34764790)
139. Grohmann, U.; Fallarino, F.; Bianchi, R.; Orabona, C.; Vacca, C.; Fioretti, M.C.; Puccetti, P. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med., 2003, 198(1), 153-160. (Pubitemid 36870195)
140. Lob, S.; Konigsrainer, A. Role of IDO in organ transplantation: promises and difficulties. Int. Rev. Immunol., 2009, 28(3-4), 185-206.
141. Jasperson, L.K.; Bucher, C.; Panoskaltsis-Mortari, A.; Mellor, A.L.; Munn, D.H.; Blazar, B.R. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood, 2009, 114(24), 5062-5070.
142. Jasperson, L.K.; Bucher, C.; Panoskaltsis-Mortari, A.; Taylor, P.A.; Mellor, A.L.; Munn, D.H.; Blazar, B.R. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood, 2008, 111(6), 3257-3265.
143. Reddy, P.; Sun, Y.; Toubai, T.; Duran-Struuck, R.; Clouthier, S.G.; Weisiger, E.; Maeda, Y.; Tawara, I.; Krijanovski, O.; Gatza, E.; Liu, C.; Malter, C.; Mascagni, P.; Dinarello, C.A.; Ferrara, J.L. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions andregulates experimental graft-versus-host disease in mice. J. Clin. Invest., 2008, 118(7), 2562-2573. (Pubitemid 351949783)
144. Zegarra-Moran, O.; Folli, C.; Manzari, B.; Ravazzolo, R.; Varesio, L.; Galietta, L.J. Double mechanism for apical tryptophan depletion in polarized human bronchial epithelium. J. Immunol., 2004, 173(1), 542-549. (Pubitemid 38797382)
145. Astigiano, S.; Morandi, B.; Costa, R.; Mastracci, L.; D'Agostino, A.; Ratto, G.B.; Melioli, G.; Frumento, G. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia, 2005, 7(4), 390-396. (Pubitemid 40664228)
146. Ghahary, A.; Li, Y.; Tredget, E.E.; Kilani, R.T.; Iwashina, T.; Karami, A.; Lin, X. Expression of indoleamine 2,3-dioxygenase in dermal fibroblasts functions as a local immunosuppressive factor. J. Invest. Dermatol., 2004, 122(4), 953-964. (Pubitemid 38580998)
147. Meisel, R.; Zibert, A.; Laryea, M.; Gobel, U.; Daubener, W.; Dilloo, D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 2004, 103(12), 4619-4621. (Pubitemid 38745993)
148. Mulley, W.R.; Li, Y.Q.; Wee, J.L.; Dodge, N.; Christiansen, D.; Simeonovic, C.; Ierino, F.L.; Sandrin, M.S. Local expression of IDO, either alone or in combination with CD40Ig, IL10 or CTLA4Ig, inhibits indirect xenorejection responses. Xenotransplantation, 2008, 15(3), 174-183. (Pubitemid 352000251)
149. Wee, J.L.; Christiansen, D.; Li, Y.Q.; Boyle, W.; Sandrin, M.S. Suppression of cytotoxic and proliferative xenogeneic T-cell responses by transgenic expression of indoleamine 2,3-dioxygenase. Immunol. Cell Biol., 2008, 86(5), 460-465. (Pubitemid 351948220)